Carl J Baldick

Summary

Affiliation: Bristol-Myers Squibb
Country: USA

Publications

  1. ncbi Hepatitis B virus quasispecies susceptibility to entecavir confirms the relationship between genotypic resistance and patient virologic response
    Carl J Baldick
    Bristol Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, USA
    J Hepatol 48:895-902. 2008
  2. ncbi A novel small molecule inhibitor of hepatitis C virus entry
    Carl J Baldick
    Bristol Myers Squibb, Research and Development, Wallingford, Connecticut, United States of America
    PLoS Pathog 6:e1001086. 2010
  3. ncbi Ultrasensitive genotypic detection of antiviral resistance in hepatitis B virus clinical isolates
    Jie Fang
    Bristol Myers Squibb Research and Development, Wallingford, CT, USA
    Antimicrob Agents Chemother 53:2762-72. 2009
  4. ncbi Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present
    Daniel J Tenney
    Bristol Myers Squibb Pharmaceutical Research Institute, 5 Research Parkway, Wallingford, CT 06492, USA
    Antimicrob Agents Chemother 51:902-11. 2007
  5. ncbi Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy
    Daniel J Tenney
    Bristol Myers Squibb Company Research and Development, Wallingford, CT 06492, USA
    Hepatology 49:1503-14. 2009
  6. ncbi Comprehensive evaluation of hepatitis B virus reverse transcriptase substitutions associated with entecavir resistance
    Carl J Baldick
    Bristol Myers Squibb Research and Development, Wallingford, CT 06492, USA
    Hepatology 47:1473-82. 2008
  7. ncbi High-throughput screening and rapid inhibitor triage using an infectious chimeric Hepatitis C virus
    Michael J Wichroski
    Bristol Myers Squibb Research and Development, Wallingford, Connecticut, United States of America
    PLoS ONE 7:e42609. 2012
  8. ncbi Inhibition of hepatitis B virus polymerase by entecavir
    David R Langley
    Bristol Myers Squibb Pharmaceutical Research Institute, 5 Research Parkway, Wallingford, CT 06443, USA
    J Virol 81:3992-4001. 2007
  9. ncbi Entecavir resistance is rare in nucleoside naïve patients with hepatitis B
    Richard J Colonno
    Bristol Myers Squibb Pharmaceutical Research Institute, Wallingford, CT 06492, USA
    Hepatology 44:1656-65. 2006
  10. ncbi Novel nonnucleoside inhibitor of hepatitis C virus RNA-dependent RNA polymerase
    Anita Y M Howe
    Infectious Diseases Wyeth Research, Pearl River, New York 10965, USA
    Antimicrob Agents Chemother 48:4813-21. 2004

Collaborators

Detail Information

Publications11

  1. ncbi Hepatitis B virus quasispecies susceptibility to entecavir confirms the relationship between genotypic resistance and patient virologic response
    Carl J Baldick
    Bristol Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, USA
    J Hepatol 48:895-902. 2008
    ..Using >500 patient HBV isolates from several entecavir clinical trials, we show that phenotypic susceptibility correlates with genotypic resistance and patient virologic responses...
  2. ncbi A novel small molecule inhibitor of hepatitis C virus entry
    Carl J Baldick
    Bristol Myers Squibb, Research and Development, Wallingford, Connecticut, United States of America
    PLoS Pathog 6:e1001086. 2010
    ..These results suggest that inhibitors of HCV entry could be added to replication inhibitors and interferons already in development...
  3. ncbi Ultrasensitive genotypic detection of antiviral resistance in hepatitis B virus clinical isolates
    Jie Fang
    Bristol Myers Squibb Research and Development, Wallingford, CT, USA
    Antimicrob Agents Chemother 53:2762-72. 2009
    ..In summary, we established and validated an ultrasensitive method for measuring resistant HBV variants in clinical specimens, which enabled earlier, quantitative measurement of resistance to therapy...
  4. ncbi Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present
    Daniel J Tenney
    Bristol Myers Squibb Pharmaceutical Research Institute, 5 Research Parkway, Wallingford, CT 06492, USA
    Antimicrob Agents Chemother 51:902-11. 2007
    ..In summary, ETV was effective in LVD-refractory patients, with resistant sequences arising from a subset of patients harboring preexisting LVDr/ETVr variants and with approximately half of the patients experiencing a virologic rebound...
  5. ncbi Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy
    Daniel J Tenney
    Bristol Myers Squibb Company Research and Development, Wallingford, CT 06492, USA
    Hepatology 49:1503-14. 2009
    ..These findings support ETV as a primary therapy that enables prolonged treatment with potent viral suppression and minimal resistance...
  6. ncbi Comprehensive evaluation of hepatitis B virus reverse transcriptase substitutions associated with entecavir resistance
    Carl J Baldick
    Bristol Myers Squibb Research and Development, Wallingford, CT 06492, USA
    Hepatology 47:1473-82. 2008
    ....
  7. ncbi High-throughput screening and rapid inhibitor triage using an infectious chimeric Hepatitis C virus
    Michael J Wichroski
    Bristol Myers Squibb Research and Development, Wallingford, Connecticut, United States of America
    PLoS ONE 7:e42609. 2012
    ..Leveraging results from this robust whole-virus assay represents a critical first step towards identifying inhibitors of novel targets to broaden the spectrum of antivirals for the treatment of HCV...
  8. ncbi Inhibition of hepatitis B virus polymerase by entecavir
    David R Langley
    Bristol Myers Squibb Pharmaceutical Research Institute, 5 Research Parkway, Wallingford, CT 06443, USA
    J Virol 81:3992-4001. 2007
    ..Overall, these studies explain the potency, mechanism, and cross-resistance profile of ETV against HBV and account for the successful treatment of naive and LVD- or ADV-experienced chronic HBV patients...
  9. ncbi Entecavir resistance is rare in nucleoside naïve patients with hepatitis B
    Richard J Colonno
    Bristol Myers Squibb Pharmaceutical Research Institute, Wallingford, CT 06492, USA
    Hepatology 44:1656-65. 2006
    ..These findings suggest that the rapid, sustained suppression of HBV replication, combined with a requirement for multiple substitutions, creates a high genetic barrier to ETVr in nucleoside naïve patients...
  10. ncbi Novel nonnucleoside inhibitor of hepatitis C virus RNA-dependent RNA polymerase
    Anita Y M Howe
    Infectious Diseases Wyeth Research, Pearl River, New York 10965, USA
    Antimicrob Agents Chemother 48:4813-21. 2004
    ..Fluorescence binding studies show that HCV-371 binds the NS5B with an apparent dissociation constant of 150 nM, leading to high selectivity and lack of cytotoxicity in the antiviral assays...
  11. ncbi Phosphorylation of human cytomegalovirus glycoprotein B (gB) at the acidic cluster casein kinase 2 site (Ser900) is required for localization of gB to the trans-Golgi network and efficient virus replication
    Michael A Jarvis
    Vaccine and Gene Therapy Institute, Oregon Health Sciences University, Portland, Oregon, USA
    J Virol 78:285-93. 2004
    ..Together, these results demonstrate that phosphorylation of gB at Ser900 is necessary for gB localization to the TGN, as well as for efficient viral replication, and further support the TGN as a site of HCMV envelopment...